Repository logo
 

Pros and cons of different therapeutic antibody formats for recombinant antivenom development.

Published version
Peer-reviewed

Change log

Authors

Laustsen, Andreas H 
María Gutiérrez, José 
Knudsen, Cecilie 
Johansen, Kristoffer H 
Bermúdez-Méndez, Erick 

Abstract

Antibody technologies are being increasingly applied in the field of toxinology. Fuelled by the many advances in immunology, synthetic biology, and antibody research, different approaches and antibody formats are being investigated for the ability to neutralize animal toxins. These different molecular formats each have their own therapeutic characteristics. In this review, we provide an overview of the advances made in the development of toxin-targeting antibodies, and discuss the benefits and drawbacks of different antibody formats in relation to their ability to neutralize toxins, pharmacokinetic features, propensity to cause adverse reactions, formulation, and expression for research and development (R&D) purposes and large-scale manufacturing. A research trend seems to be emerging towards the use of human antibody formats as well as camelid heavy-domain antibody fragments due to their compatibility with the human immune system, beneficial therapeutic properties, and the ability to manufacture these molecules cost-effectively.

Description

Keywords

Adverse reactions, Animal envenoming, Antibodies, Antibody expression, Antivenom, Antivenom design, Biotechnology, Immunogenicity, Neglected tropical diseases, Pharmacodynamics, Pharmacokinetics, Recombinant antivenom, Scorpion sting, Snakebite, Spider bite, Venom, Venom neutralization, Animals, Antibodies, Antivenins, Camelus, Humans, Recombinant Proteins, Venoms

Journal Title

Toxicon

Conference Name

Journal ISSN

0041-0101
1879-3150

Volume Title

146

Publisher

Elsevier BV